Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
Vobra-duo is discontinued at long last.
The company’s matching strategy for CB-010 will soon be put to the test.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
